U.S. Elections, Covid-19 Vaccine News Provide Mixed Results For Hedge Funds
The recent news relating to the U.S. Presidential election and the Pfizer-sponsored Covid-19 vaccine provided hedge funds with mixed results, according to Lyxor Asset Management's Cross-Asset Research Weekly Brief.
Post-election, all strategies were up, led by L/S Equity, Special Situation, and Global Macro. In contrast, returns were milder and uneven after the vaccine announcement. Whilst the news was most beneficial for Special Situation and L/S Credit strategies (boosted by their beta rather than by their alpha, according to Lyxor), it was painful for CTAs and some Global Macro funds. Despite that, these funds haven't changed their positioning much at all, according to the report.
"CTAs have not substantially modified their exposures, still modestly short DM equities but adding to EM equities. They also kept their long dollar and bonds. Global Macro had raised equity exposures in October and only marginally added to them since last week. They continue to shave off their bond holdings, while remaining tactically neutral+ on USD. EM and China hedge funds were cautious ahead of U.S. elections but are now adding risk."
L/S Equity returns were highly dispersed; caught off guard, managers overweighing Growth and “work-from-home” stocks at the expense of Value and Covid-19’s prime victims were severely hit, especially in Europe given the rally in financial and airlines stocks.
"Long positions contributed positively but shorts faced a major squeeze, hitting Quant and L/S Neutral strategies with a double whammy," says the report. "L/S Equity portfolios were already positioned for U.S. elections and were little changed thereafter. The knee-jerk reaction after the vaccine news was to cover shorts while reducing their long positions (resulting in lower gross exposures)."
© The Sortino Group Ltd
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.